

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4516664

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	RECRO IRELAND LIMITED	07/24/2017
RECEIVING PARTY DATA		
Name:	RECRO PHARMA, INC.	
Street Address:	490 LAPP ROAD	
City:	MALVERN	
State/Country:	PENNSYLVANIA	
Postal Code:	19355	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Patent Number:	8512727
CORRESPONDENCE DATA		
Fax Number:	(610)640-1965	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	610.651.2277	
Email:	chill@stradley.com	
Correspondent Name:	PAUL K. LEGAARD, ESQ.	
Address Line 1:	30 VALLEY STREAM PARKWAY	
Address Line 2:	STRADLEY RONON STEVENS & YOUNG, LLP	
Address Line 4:	MALVERN, PENNSYLVANIA 19355-1481	
ATTORNEY DOCKET NUMBER:	189109.00901 (3106)	
NAME OF SUBMITTER:	CATHERINE HILL	
SIGNATURE:	/Cathy1/	
DATE SIGNED:	07/24/2017	
Total Attachments: 3		
source=Asn-RecroIrelandLimitedRecroPharmaInc#page1.tif		
source=Asn-RecroIrelandLimitedRecroPharmaInc#page2.tif		
source=Asn-RecroIrelandLimitedRecroPharmaInc#page3.tif		

CORPORATION TO CORPORATION

Witness

ASSIGNMENT

WHEREAS, Recro Ireland Limited, hereinafter referred to as the ASSIGNOR, a corporation of Ireland, having its principal place of business at 25/28 North Wall Quay, Dublin 1, Ireland D01 H104, is the owner of certain inventions or improvements for which at least an application for Letters Patent of the United States has been made, said application entitled "Nanoparticulate Meloxicam Formulations," and said application having been assigned Application Serial No. 10/784,900 (now U.S. Patent No. 8,512,727) (hereafter, PATENT PROPERTY); and

WHEREAS, Recro Pharma, Inc., hereinafter referred to as the ASSIGNEE, a corporation of Pennsylvania, having its principal place of business at 490 Lapp Road, Malvern, Pennsylvania 19355, is desirous of acquiring the entire right, title and interest in and to said PATENT PROPERTY in any and all countries;

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR, intending to be legally bound, has sold, assigned, transferred and set over, and by these presents do hereby sell, assign, transfer and set over to said ASSIGNEE, the entire right, title, benefit and interest in and to said PATENT PROPERTY and any and all continuations, divisions and renewals of and substitutes for said PATENT PROPERTY and to and under any and all additional Letters Patent which may be granted on or as a result thereof in the United States, and any reissue or reissues or extension or extensions of said Letters Patent, and the entire right, title, and interest in said invention and/or improvements for all foreign countries, including all priority rights under the Paris Convention, and agrees to execute, at the request of said ASSIGNEE or its assignees, all documents in connection with any application for foreign Letters Patent therefore, and the full right to sue for and recover all profits and damages recoverable for past infringement of the same, and the right to claim priority, and assign to and authorize said ASSIGNEE to file applications for Letters Patent in the United States

CORPORATION TO CORPORATION

Witness

and all foreign countries, the same to be held and enjoyed by said ASSIGNEE, its successors, assigns, nominees or legal representatives, to the full end of the term or terms for which said Letters Patent respectively may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment, sale and transfer not been made.

AND it is hereby covenanted that ASSIGNOR has full right to convey its entire interest herein assigned, and that ASSIGNOR has not executed and will not execute any agreement in conflict herewith, and ASSIGNOR further covenants and agrees that it will each time a request is made and without undue delay, execute and deliver all such papers as may be necessary or desirable to perfect the title to said PATENT PROPERTY in said ASSIGNEE, its successors, assigns, nominees, or legal representatives, and ASSIGNOR agrees to communicate to said ASSIGNEE or to its nominee all known facts respecting said PATENT PROPERTY, to testify in any legal proceedings, to sign all lawful papers, to execute all disclaimers and divisional, continuing, reissue and foreign applications, to make all rightful oaths, and generally to do everything possible to aid said ASSIGNEE, its successors, assigns, nominees and legal representatives to obtain and enforce for its or their own benefit proper patent protection for said PATENT PROPERTY in any and all countries, all at the expense, however, of said ASSIGNEE, its successors, assigns, nominees, or legal representatives.

AND ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue to said ASSIGNEE, as assignee of the entire right, title and interest, any and all Letters Patent for said PATENT PROPERTY, including any and all Letters Patent of the United States which may be issued and granted on or as a result of any applications in said PATENT PROPERTY, in accordance with the terms of this ASSIGNMENT.

CORPORATION TO CORPORATION


Witness

AND if the invention requires a biological deposit, ASSIGNOR also hereby grants to ASSIGNEE such control over any deposit made by ASSIGNOR as may be necessary to the validity of the patent rights assigned herein.

IN WITNESS WHEREOF, the undersigned, being properly authorized to execute this ASSIGNMENT, hereunto sets their hand and seal.

**GIVEN UNDER THE COMMON SEAL
of RECRO IRELAND LIMITED**
in the presence of:





Director (Brian Harrison)



Company Secretary (by Charles Carroll an
authorized signatory of Goodbody Secretarial
Limited)

DATED: JULY 24, 2017